Fierce Pharma
JANUARY 3, 2024
As the J.P. | As the J.P. Morgan Healthcare Conference rolled on in San Francisco, BioNTech, Alnylam and many other companies updated investors on their strategies heading into 2024.
MedCity News
JANUARY 3, 2024
Goldman Sachs’s new fund—its first dedicated to life sciences—will focus on early- to mid-stage therapeutics companies with multiple assets. Genetic medicine, cell therapy, immunotherapy, and artificial intelligence are among the areas of investment interest for the firm.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JANUARY 3, 2024
Gene therapies have been approved for certain patients with beta thalassemia. After a successful phase 3 readout, Agios hopes it can reach a unique subgroup and eventually all patients. | Gene therapies have been approved for certain patients with beta thalassemia. After a successful phase 3 readout, Agios hopes it can reach a unique subgroup and eventually all patients.
MedCity News
JANUARY 3, 2024
Aetna Better Health of Kentucky, Avēsis and MapHabit have teamed up to support 200 Kentucky children with autism or intellectual disabilities. The pilot program will help the patients with activities of daily living, such as oral hygiene.
Fierce Pharma
JANUARY 3, 2024
As the J.P. Morgan Healthcare Conference moves into its third day, we're covering the latest developments here. | On Wednesday at the the J.P. Morgan Healthcare Conference, attendees will get a chance to hear from AbbVie, Amarin and several other pharmaceutical companies.
MedCity News
JANUARY 3, 2024
On New Year’s Day, two Missouri health systems — St. Louis-based BJC HealthCare and Kansas City-based St. Luke’s Health System — officially completed their merger. The combined health system comprises 28 hospitals and hundreds of clinics serving 6 million people, and it is expected to generate $10 billion in annual revenue.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
JANUARY 3, 2024
By leveraging analytics to optimize the patient experience in clinical trials, patient attrition will decrease, improving clinical outcomes and research goals.
Fierce Pharma
JANUARY 3, 2024
As the J.P. Morgan Healthcare Conference kicked off in San Francisco, EY released its annual report on the industry's dealmaking firepower. | As the J.P. Morgan Healthcare Conference kicked off in San Francisco, EY released its annual report on the industry's dealmaking firepower. Plus, Moderna, bluebird and other companies updated investors on their businesses heading into 2024.
MedCity News
JANUARY 3, 2024
Medical device startup CardioMech raised $13 million to advance the development and validation of its flagship device, which is designed to treat degenerative mitral valve regurgitation. The catheter-based device seeks to offer an uncomplicated, direct procedure for patients eligible for open-heart surgery as well as those considered eligible for the surgery.
Fierce Pharma
JANUARY 3, 2024
After a pair of high-profile approvals for sickle cell disease gene ther | After a pair of high-profile approvals for sickle cell disease gene therapies in the U.S. last month, Pfizer is ushering in the New Year with a regulatory endorsement for its hemophilia B gene therapy north of the border.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
JANUARY 3, 2024
The evolution of ECMO from a last-resort intervention to a mainstay of modern critical care is a testament to the relentless pursuit of better patient outcomes in the field of medicine. Unfortunately, despite the immense life-saving capability of this therapy, it remains vastly underutilized.
Fierce Pharma
JANUARY 3, 2024
When GSK laid out $90 million upfront to acquire rights to Scynexis’ antifungal Brexafemme last spring, the British pharma threw a lifeline to a company whose blockbuster launch ambitions had hit t | GSK has downgraded a licensing deal for Scynexis' antifungal ibrexafungerp following an ongoing recall of the drug's approved form, Brexafemme.
European Pharmaceutical Review
JANUARY 3, 2024
Korserdu ® (elacestrant) is the first treatment indicated for ER+, HER2- advanced or metastatic breast cancer tumours with ESR1 mutations. The endocrine therapy has been granted a marketing authorisation by the UK Medicines & Healthcare products Regulatory Agency (MHRA). This represents the first endocrine therapy innovation in nearly 20 years. The small molecule treatment is authorised for postmenopausal women, and men, with oestrogen receptor (ER)-positive, HER2-negative, locally advanced
Fierce Pharma
JANUARY 3, 2024
After a dispute over milestone payments derailed a 2019 heart med collaboration, Daiichi Sankyo and Esperion Therapeutics have mended fences with a $125 million settlement. | The agreement amends terms of the companies' 2019 partnership on heart med Nexletol and dismisses Esperion's lawsuit over milestone payments ahead of a potential European label expansion.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
JANUARY 3, 2024
The UK medicines regulator has launched its mutual recognition framework for authorising medicines in a move that it says will help to bring new drugs to patients in the UK more quickly.
Fierce Pharma
JANUARY 3, 2024
Welcome to 2024's regulatory tracker for Fierce Pharma. | In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.
Pharmaceutical Technology
JANUARY 3, 2024
A new report from Novotech delves into the multifaceted landscape of HIV, focusing on its impact, treatment, and global initiatives.
European Pharmaceutical Review
JANUARY 3, 2024
Outsourcing has become a necessity for many pharmaceutical companies; even the outsourcing of regulatory functions has grown over the past several years and is expected to increase steadily in future. The pharmaceutical regulatory affairs outsourcing market is thus projected to rise from $7 billion in 2022 to $15 billion in 2032, 1 driven by the growing number of clinical trial applications (see Figure 1 ) 2 and product registrations.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
pharmaphorum
JANUARY 3, 2024
UK report calls for the mothballed Rosalind Franklin Lab to be repurposed as a manufacturing unit to support clinical trials of bacteriophages as new antimicrobial agents
Pharmaceutical Technology
JANUARY 3, 2024
This collaboration comes six years after the German company Boehringer signed two agreements to develop treatments for NASH.
European Pharmaceutical Review
JANUARY 3, 2024
What are the top trends relating to sterility testing of ATMPs? For me, one of the most promising developments involves the use of the next-generation sequencing-based sterility test (NGSST), which uses whole genome amplification and sequencing followed by microorganism identification with 48 hours. 1 This method removes the requirements for a culture period and has a higher accuracy than other rapid testing methods such as ATP bioluminescence.
Pharmaceutical Technology
JANUARY 3, 2024
Novartis will pay Voyager $100m upfront and up to $1.2bn in milestone-based payments and royalties on net sales.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
PharmaTimes
JANUARY 3, 2024
NaviCam ProScan is the first AI-assisted reading tool for gastrointestinal bleeding
Pharmaceutical Technology
JANUARY 3, 2024
The first of a two-part series on therapies that receive an FDA priority review designation dives into how these vouchers incentivise innovation for low-commercial value-diseases.
PharmaTimes
JANUARY 3, 2024
The new hub will be located in the King’s Cross Knowledge Quarter, London
Contrarian Sales Techniques
JANUARY 3, 2024
Navigating through a week in the sales world is like embarking on a mini-adventure, each day bringing its own set of challenges and triumphs. Let's break down the weekly routine of a sales superstar into beginning, middle, and end segments. This isn't just about getting through the week. It's about maximizing each day to its fullest potential. So, let's turn the pages of this weekly planner together.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
PharmExec
JANUARY 3, 2024
VYD222 is a broadly neutralizing, half-life extended monoclonal antibody developed specifically to prevent COVID-19 in immunocompromised adults and adolescents.
Rep-Lite
JANUARY 3, 2024
Medical sales is the field of selling medical products and services to healthcare providers, such as hospitals, doctors, and clinics. Medical sales representatives typically work for pharmaceutical companies, medical device manufacturers, or healthcare service providers. Medical sales reps play a vital role in bringing new and innovative products and treatments to the market.
Contrarian Sales Techniques
JANUARY 3, 2024
I'm back, and this time we're diving into the midday routine of a sales superstar. You know, that crucial part of the day when energy levels can either skyrocket or take a nosedive. It's the halftime of your workday, and how you spend it can really set the tone for the second act. So, grab your favorite midday snack, and let's unwrap the secrets to keeping that sales spark alive post-noon.
Penrod
JANUARY 3, 2024
The Heart of Salesforce Managed Services Since our founding in 2011, we’ve met and exceeded the standards for world-class Salesforce support by setting our sights on enhancing efficiency for our clients. Our services model revolves around focusing only on the healthcare industry. Penrod is proud to announce that our recent Managed Services Expert Navigator status has positioned us as one of the top three solution integrators for Salesforce services in the Healthcare and Life Sciences indus
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
289 
Let's personalize your content